VCYT Q4 2023 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$98M+22.3% YoY

Gross Profit

$69M70.1% margin

Operating Income

-$36M-36.2% margin

Net Income

-$28M-28.8% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

+9.0%

Cash Flow

Operating Cash Flow

$16M

Free Cash Flow

$13M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$71M

Stockholders' Equity

$1.0B

Cash & Equivalents

$216M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$98M	$80M	+22.3%
Gross Profit	$69M	$53M	+28.7%
Operating Income	-$36M	-$5M	-555.1%
Net Income	-$28M	-$4M	-636.0%

Revenue Segments

Testing

$90M92%

Biopharmaceutical And Other

$4M4%

Product

$4M4%

Geographic Segments

UNITED STATES

$335M93%

Non-US

$27M7%